However, several big pharma firms have entered the space in the past few years including Regeneron, which invested $800 million in Alnylam in 2019, and Novartis, which cited the potential of RNAi in its $9.7 billion acquisition of the Medicines Co.ДicernaвЂ™s GalXC RNAi and GalXC-Plus platforms target specific genes to maximize pharmaceutical acceptability by enabling access to intracellular disease targets across hepatic and extrahepatic cell and tissue types. The modality is relatively new with only three RNAi drugs approved by the US Food and Drug Administration (FDA) to date: Onpattro (patisiran) in 2018, Givlaari (givosiran) in 2019, and Oxlumo (lumasiran) in 2020 вЂ“ all developed by Alnylam.

Ribonucleic acid interference (RNAi) drugs silence a gene before it can produce a disease-causing protein. вЂњWe build on our successful collaboration and by combining DicernaвЂ™s state-of-the-art RNAi drug engine and intracellular delivery with our deep capabilities in disease biology understanding and tissue targeting through peptides and proteins we have the potential to expand our pipeline and deliver life-changing precision medicines for people living with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH as well as rare diseases like endocrine disorders and bleeding disorders.вЂќ

вЂњThe acquisition of Dicerna accelerates Novo NordiskвЂ™s research within RNAi and expands the usage of the RNAi technology,вЂќ said Marcus Schindler, chief scientific officer of Novo Nordisk.

Serious sam 1 engine